It is worth pointing out that, in most studies, anti‐PD‐L1 or other ICB is given as a separate systemic therapy; however, in Le's study, decorating anti‐PD‐L1 antibody on the surface of a nanoparticle containing immune adjuvant served 3 functions: First, it behaved as an active tumor‐targeting ligand that enhanced the tumor accumulation of nanoparticles; second, it facilitated the formation of an in situ vaccine that enabled the codelivery of tumor antigens and adjuvants to the same APC; and third, it blocked the immune checkpoint PD‐L1 in tumor cells. The gene discussed is CD274; the disease is neoplasm.